Rational approach to implementation of prostate cancer antigen 3 into clinical care (Q39888907)

15 September 2017

Rational approach to implementation of prostate cancer antigen 3 into clinical care (English)

1 reference

15 September 2017

1 reference

Rou Wang

1

1 reference

15 September 2017

Arul M Chinnaiyan

2

1 reference

15 September 2017

Rodney L Dunn

3

1 reference

15 September 2017

Kirk J Wojno

4

1 reference

15 September 2017

John T Wei

5

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

15 September 2017

1 reference

15 September 2017

115

1 reference

15 September 2017

17

1 reference

15 September 2017

3879-3886

1 reference

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

PCA3: a molecular urine assay for predicting prostate biopsy outcome

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

uPM3, a new molecular urine test for the detection of prostate cancer.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

When to biopsy and when to stop biopsying

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Phases of biomarker development for early detection of cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Purification of a human prostate specific antigen

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Prostate-specific antigen levels as a predictor of lethal prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2746943

Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study

20 August 2018

1 reference

12 December 2020

A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer

1 reference

12 December 2020

Comparison of 6 Automated Assays for Total and Free Prostate-Specific Antigen with Special Reference to Their Reactivity toward the WHO 96/670 Reference Preparation

1 reference

12 December 2020

Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.24447

1 reference

release_hqq3vkmwlzgaxhlfypzbhl6v54

15 September 2017

0 references

1 reference

15 September 2017

1 reference